DE69712731T2 - Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten - Google Patents
Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patientenInfo
- Publication number
- DE69712731T2 DE69712731T2 DE69712731T DE69712731T DE69712731T2 DE 69712731 T2 DE69712731 T2 DE 69712731T2 DE 69712731 T DE69712731 T DE 69712731T DE 69712731 T DE69712731 T DE 69712731T DE 69712731 T2 DE69712731 T2 DE 69712731T2
- Authority
- DE
- Germany
- Prior art keywords
- hiv
- chimeric
- sensitivity
- inhibitor
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96200175 | 1996-01-26 | ||
PCT/IB1997/000071 WO1997027480A1 (en) | 1996-01-26 | 1997-01-24 | Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69712731D1 DE69712731D1 (de) | 2002-06-27 |
DE69712731T2 true DE69712731T2 (de) | 2003-02-06 |
Family
ID=8223611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69712731T Expired - Lifetime DE69712731T2 (de) | 1996-01-26 | 1997-01-24 | Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten |
Country Status (21)
Country | Link |
---|---|
US (3) | US6221578B1 (de) |
EP (1) | EP0877937B1 (de) |
KR (1) | KR100495690B1 (de) |
CN (2) | CN1991365A (de) |
AT (1) | ATE217971T1 (de) |
AU (1) | AU717755B2 (de) |
BG (1) | BG102710A (de) |
BR (1) | BR9707204A (de) |
CZ (1) | CZ292899B6 (de) |
DE (1) | DE69712731T2 (de) |
ES (1) | ES2177922T3 (de) |
HU (1) | HU226203B1 (de) |
IL (1) | IL125442A (de) |
IS (1) | IS4799A (de) |
NO (1) | NO321329B1 (de) |
NZ (1) | NZ325912A (de) |
PL (1) | PL186473B1 (de) |
SK (1) | SK283878B6 (de) |
TR (1) | TR199801443T2 (de) |
WO (1) | WO1997027480A1 (de) |
ZA (1) | ZA97669B (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0656887T3 (da) | 1992-08-25 | 1999-07-05 | Searle & Co | Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser |
US20030220276A1 (en) * | 1995-05-16 | 2003-11-27 | Opendra Narayan | HIV vaccine and method of use |
US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US20070010471A1 (en) * | 1997-05-02 | 2007-01-11 | Opendra Narayan | HIV DNA vaccine |
JP2001512036A (ja) * | 1997-07-30 | 2001-08-21 | バイアラジック・インコーポレーテッド | 抗ウイルス薬剤感受性および耐性を測定するための組成物および方法、並びに抗ウイルス薬剤をスクリーニングするための組成物および方法 |
MXPA00011623A (es) * | 1998-05-26 | 2002-10-17 | Virologic Inc | Medios y metodos para verificar la terapia antirretroviral con inhibidor no nucleosidico de la transcriptasa inversa. |
BR0011555A (pt) * | 1999-05-28 | 2002-02-26 | Virco Nv | Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga |
US6800437B1 (en) | 1999-08-06 | 2004-10-05 | Tibotec Bvba | Method of monitoring a biological system by labeling with an apo metal binding protein |
EP1109019A1 (de) * | 1999-12-15 | 2001-06-20 | BioStrands S.r.l. | Verfahren zur Ermittlung der Empfindlichkeit von HIV-Varianten gegen Hemmstoffe der HIV-Protease |
WO2001057245A2 (en) * | 2000-02-04 | 2001-08-09 | K.U.Leuven Research & Development | Hiv-1 resistance assay |
GB0009374D0 (en) * | 2000-04-14 | 2000-05-31 | Glaxo Group Ltd | Phenotyping assay and reagents therefor |
WO2001079540A2 (en) * | 2000-04-18 | 2001-10-25 | Virco Bvba | Methods for measuring drug resistance |
CA2406830C (en) * | 2000-04-20 | 2012-10-02 | Virco Bvba | Method for mutation detection in hiv using pol sequencing |
US6800463B1 (en) * | 2000-04-20 | 2004-10-05 | Virco Bvba | Method for mutation detection in HIV-1 using pol sequencing |
US6582901B2 (en) * | 2000-04-26 | 2003-06-24 | Bruce K. Patterson | Cell specific anti-viral drug susceptibility test using tagged permissive target cells |
US7058616B1 (en) | 2000-06-08 | 2006-06-06 | Virco Bvba | Method and system for predicting resistance of a disease to a therapeutic agent using a neural network |
WO2001096611A1 (en) * | 2000-06-12 | 2001-12-20 | Virologic, Inc. | Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
US6582920B2 (en) * | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
WO2002033638A2 (en) | 2000-10-20 | 2002-04-25 | Virco Bvba | Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
AU1234402A (en) * | 2000-10-20 | 2002-04-29 | Virco Nv | Establishment of biological cut-off values for predicting resistance to therapy |
US7306901B2 (en) | 2001-08-08 | 2007-12-11 | Tibotec Pharmaceuticals, Ltd. | Methods and means for assessing HIV envelope inhibitor therapy |
US6958211B2 (en) * | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
ES2302860T3 (es) | 2001-11-08 | 2008-08-01 | Tibotec Pharmaceuticals Ltd. | Ensayo de proteasas para la monitorizacion terapeutica de farmacos. |
WO2004003817A1 (en) | 2002-07-01 | 2004-01-08 | Tibotec Pharmaceuticals Ltd. | Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance |
US7473524B2 (en) | 2002-07-01 | 2009-01-06 | Hilde Azijn | Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance |
EP1728186A2 (de) | 2004-03-02 | 2006-12-06 | Virco Bvba | Schätzung von klinischen kritischen werten |
WO2007065926A1 (en) | 2005-12-07 | 2007-06-14 | Tibotec Pharmaceuticals Ltd. | Methods, plasmid vectors and primers for assessing hiv viral fitness |
US20100009341A1 (en) * | 2006-04-14 | 2010-01-14 | Inky Paul Madeleine De Baere | Methods and means for assessing hiv gag/protease inhibitor therapy |
US20100173282A1 (en) | 2007-05-25 | 2010-07-08 | Tibotec Pharmaceuticals Ltd. | Mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance |
ES2546190T3 (es) * | 2008-10-06 | 2015-09-21 | Janssen Diagnostics Bvba | Método para determinar mutaciones de resistencia a fármacos en cualquiera de las regiones de proteína no estructural NS3 a NS5B del virus de la hepatitis C (HCV) para los genotipos 1 a 6 |
WO2010130731A1 (en) * | 2009-05-12 | 2010-11-18 | Virco Bvba | Hiv-1-c resistance monitoring |
CN107085093B (zh) * | 2017-03-24 | 2019-06-21 | 西藏诺迪康药业股份有限公司 | 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3875396A (en) * | 1973-11-12 | 1975-04-01 | Illuminite Corp | Illuminated clipboard |
US4675147A (en) * | 1983-04-06 | 1987-06-23 | Westinghouse Electic Corp. | Generating an integrated graphic display of the safety status of a complex process plant |
US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
DK0406557T3 (da) | 1989-05-25 | 2002-02-11 | Univ Duke | Multivalent repressor af genfunktion |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
JPH05148202A (ja) * | 1991-04-10 | 1993-06-15 | Tsumura & Co | 新規な化合物およびその医薬としての用途 |
WO1993023574A1 (en) | 1992-05-14 | 1993-11-25 | Kozal Michael J | Polymerase chain reaction assays for monitoring antiviral therapy |
US5733720A (en) | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
WO1994001584A1 (en) | 1992-07-06 | 1994-01-20 | President And Fellows Of Harvard College | Methods and diagnostic kits for determining toxicity utilizing bacterial stress promoters fused to reporter genes |
US5344846A (en) | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
US5591579A (en) | 1993-12-21 | 1997-01-07 | Washington University | Indicator cell line for detecting RNA viruses and method therefor |
US6063562A (en) | 1994-09-16 | 2000-05-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst |
US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
AU6941196A (en) | 1995-09-15 | 1997-04-17 | Samir Chachoua | Method for the identification and therapeutic use of disease-associated organisms, elements and forces |
US5885806A (en) * | 1995-11-28 | 1999-03-23 | The Johns Hopkins University School Of Medicine | Methods to prepare conditionally replicating viral vectors |
AP9801360A0 (en) | 1996-01-29 | 1998-12-31 | Virologic Incorporated | Compositions and methods ofr determining anti-viral drug susceptibility and resistance and anti-viral drug screening. |
US5837464A (en) | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US5945276A (en) | 1996-04-10 | 1999-08-31 | Signal Pharmaceuticals, Inc. | Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression |
US5939253A (en) | 1996-04-26 | 1999-08-17 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting viral infection |
DE69824763T2 (de) | 1997-04-07 | 2005-07-07 | Bioimage A/S | Verfahren zum Screenen von Substanzen die einen effekt auf intrazelluläre Translokation haben |
US6365347B1 (en) | 1997-04-11 | 2002-04-02 | The Regents Of The University Of California | Method for identifying disruptors of biological pathways using genetic selection |
WO1998059074A1 (en) | 1997-06-23 | 1998-12-30 | Emory University | Human immunodeficiency viruses causing aids in a nonhuman primate |
US5976813A (en) | 1997-12-12 | 1999-11-02 | Abbott Laboratories | Continuous format high throughput screening |
-
1997
- 1997-01-24 AT AT97900712T patent/ATE217971T1/de active
- 1997-01-24 CZ CZ19982335A patent/CZ292899B6/cs not_active IP Right Cessation
- 1997-01-24 US US09/117,217 patent/US6221578B1/en not_active Expired - Lifetime
- 1997-01-24 KR KR10-1998-0705747A patent/KR100495690B1/ko not_active IP Right Cessation
- 1997-01-24 TR TR1998/01443T patent/TR199801443T2/xx unknown
- 1997-01-24 HU HU9902618A patent/HU226203B1/hu not_active IP Right Cessation
- 1997-01-24 DE DE69712731T patent/DE69712731T2/de not_active Expired - Lifetime
- 1997-01-24 NZ NZ325912A patent/NZ325912A/xx not_active IP Right Cessation
- 1997-01-24 EP EP97900712A patent/EP0877937B1/de not_active Expired - Lifetime
- 1997-01-24 PL PL97328069A patent/PL186473B1/pl not_active IP Right Cessation
- 1997-01-24 CN CNA2006101685069A patent/CN1991365A/zh active Pending
- 1997-01-24 BR BR9707204-4A patent/BR9707204A/pt not_active Application Discontinuation
- 1997-01-24 CN CN97191904A patent/CN1209875A/zh active Pending
- 1997-01-24 IL IL12544297A patent/IL125442A/en not_active IP Right Cessation
- 1997-01-24 AU AU13168/97A patent/AU717755B2/en not_active Ceased
- 1997-01-24 WO PCT/IB1997/000071 patent/WO1997027480A1/en not_active Application Discontinuation
- 1997-01-24 ES ES97900712T patent/ES2177922T3/es not_active Expired - Lifetime
- 1997-01-24 SK SK1002-98A patent/SK283878B6/sk not_active IP Right Cessation
- 1997-12-27 ZA ZA9700669A patent/ZA97669B/xx unknown
-
1998
- 1998-07-16 NO NO19983300A patent/NO321329B1/no not_active IP Right Cessation
- 1998-07-20 IS IS4799A patent/IS4799A/is unknown
- 1998-08-20 BG BG102710A patent/BG102710A/xx unknown
-
2000
- 2000-12-14 US US09/735,487 patent/US6528251B2/en not_active Expired - Fee Related
-
2003
- 2003-01-15 US US10/342,188 patent/US20030152917A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69712731T2 (de) | Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten | |
Konigsberg | Migration models of prehistoric postmarital residence | |
Martin | Nucleic acid chaperone properties of ORF1p from the non-LTR retrotransposon, LINE-1 | |
Reeves et al. | Too much of a good thing: mechanisms of gene action in Down syndrome | |
Moens et al. | Chromosome number of a small protist: accurate determination | |
Hunter et al. | Letting the genome out of the bottle-will we get our wish? | |
Aune et al. | Epigenetic activation and silencing of the gene that encodes IFN-γ | |
Mostowy et al. | The role of recombination for the coevolutionary dynamics of HIV and the immune response | |
McLachlan et al. | Functional characterization of oculodentodigital dysplasia-associated Cx43 mutants | |
Elsner et al. | Absence of cGAS-mediated type I IFN responses in HIV-1–infected T cells | |
Chatterjee et al. | Serial number tagging reveals a prominent sequence preference of retrotransposon integration | |
Riou et al. | Severe symptomatic primary human cytomegalovirus infection despite effective innate and adaptive immune responses | |
Xue et al. | The functional and evolutionary impacts of human-specific deletions in conserved elements | |
van den Ham et al. | From the two-dimensional Th1 and Th2 phenotypes to high-dimensional models for gene regulation | |
Roy Chowdhury et al. | NK-like CD8+ γδ T cells are expanded in persistent Mycobacterium tuberculosis infection | |
Fitch et al. | Evolutionary rates in proteins: neutral mutations and the molecular clock | |
Berrocal et al. | Unified bursting strategies in ectopic and endogenous even-skipped expression patterns | |
Chen et al. | Methods taught in dental schools for determining the posterior palatal seal region. | |
Dawson et al. | Electrochemical noise--some new developments in corrosion monitoring | |
DE60018117D1 (de) | Methodologie um pflanzen und andere organismen mit von der normalen probe abweichenden charakteristiken zu identifizieren | |
Chau et al. | IFN-γ gene expression is controlled by the architectural transcription factor HMGA1 | |
Larson | A reevaluation of the relationship between genome size and genetic variation | |
Phillips | Caregiving and ethnicity | |
Grob et al. | Functional insulator scanning of CpG islands to identify regulatory regions of promoters using CRISPR | |
Pendleton | AN INVESTIGATION OF THE RELATIONSHIP BETWEEN FAMILY FUNCTIONING AND SOCIAL SKILLS DEFICITS IN LEARNING DISABLED POPULATIONS (MCMASTER FAMILY ASSESSMENT DEVICE; SOCIAL COMPETENCE, SYSTEMS THEORY) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |